P081 - Predicting bone metastasis on pretreatment imaging in men with intermediate or high risk prostate cancer: A nationwide, population-based study
Publication date: November 2018Source: European Urology Supplements, Volume 17, Issue 14Author(s): R. Arnsrud Godtman, M. Månsson, O. Bratt, D. Robinsson, E. Johansson, P. Stattin, H. Kiölhede
This study contributes with the discussion about the development of the molecular profiling of prostate cancer. The further development of similar studies could help in stratifying specific risk groups, leading to a more personalized therapeutic decision for prostate cancer treatment. PMID: 31826177 [PubMed - in process]
CONCLUSION: this evidence enhances and deepens the knowledge disclosed in the literature and contributes to the strengthening of nursing care actions when dealing with the sick. PMID: 31826165 [PubMed - in process]
Condition: Prostate Cancer Interventions: Radiation: Conventionally-fractionated WPRT; Radiation: Hypofractionated WPRT Sponsors: Lawson Health Research Institute; Canadian Association of Radiation Oncology; AbbVie Not yet recruiting
CONCLUSION: Primary Signet ring cell carcinoma of the prostate is a rare and aggressive histological variant of adenocarcinomas of the prostate. Treatment is the same as classical adenocarcinoma with an emphasis on aggressive multimodal treatment. PMID: 31823856 [PubMed - in process]
Authors: Yalcin S, Kaya E, Ebiloglu T, Akay S, Zor M, Sarıkaya S, Yilmaz S, Bedir S Abstract OBJECTIVES: In this research, we designed a cognitive fusion(CF) prostate biopsy(PB) (CFPB) technique by examining the multiparametric MRI of prostate (MP_MRI-P) images in a smart-phone near the trans-rectal ultrasound (TRUS) device, and examined the results. METHODS: Between January 2011 and January 2017, a total of 344 men who had PB enrolled in this study. Group 1 had a minimum of a 12-core standard TRUS PB (TRUSPB). Group 2 had CFPB while examining the MP_ MRI-P images in a smartphone near the TRUS device. A minimu...
Authors: Murray NP, Aedo S, Fuentealba C, Salazar A, Reyes E, Lopez MA, Minzer S Abstract INTRODUCTION: Minimal residual disease (MRD) is that which persists after curative treatment for prostate cancer. It has the potential to grow and cause metastasis. The detection of circulating prostate cells (CPCs) and bone marrow micro-metastasis could represent different sub-types of MRD. OBJECTIVE: To determine biochemical failure free survival and time to failure, the presence of circulating prostate cells and bone marrow micro-metastasis in men treated for low risk prostate cancer. HYPOTHESIS: The presence of MRD...
In conclusion, the present study demonstrated that PCAT19 negatively regulates the p53 tumor-suppression pathway, promoting cancer cell proliferation in patients with NSCLC. PMID: 31819778 [PubMed]
In conclusion, NKX3.1 shows routine expression in Sertoli cells and P501S shows routine expression in Leydig cells and rete testis epithelium. In addition, these markers can be positive in sex cord-stromal tumors and rete testis adenocarcinoma.
CONCLUSIONS: Neither a diagnosis of prostate cancer nor ADT use was associated with odds of MCI in this cross-sectional population-based study. PMID: 31821185 [PubMed - as supplied by publisher]
AbstractAndrogen deprivation therapy (ADT) has been the cornerstone of prostate cancer treatment. ADT delays cancer progression, alleviates cancer-related symptoms, and is associated with survival gains. Despite these established benefits, the extended duration of therapy comes with known side effects. Furthermore, research from the past decade has generated increased awareness for more potentially lethal cardiometabolic consequences of ADT. In this review, we explore the relationship between ADT and cardiometabolic effects. Current literature on this complex relationship remains conflicting, due to a variety of factors, i...